Iyad Alnahhas1, Appaji Rayi2, Joshua D Palmer3, Raju Raval3, Edmund Folefac4, Shirley Ong5, Pierre Giglio5, Vinay Puduvalli6. 1. Division of Neuro-Oncology, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania. 2. Department of Neurology, Charleston Area Medical Center, Charleston, West Virginia. 3. Department of Radiation Oncology, the Ohio State University Wexner Medical Center, Columbus, Ohio. 4. Division of Medical Oncology, the Ohio State University Wexner Medical Center, Columbus, Ohio. 5. Division of Neuro-Oncology, Department of Neurology, the Ohio State University Wexner Medical Center, Columbus, Ohio. 6. Department of Neurology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: Radiation necrosis (RN) is a potential complication after radiation therapy for brain tumors. It is hypothesized that VEGF plays an important role in the pathophysiology of RN. Bevacizumab, a monoclonal antibody against VEGF-A, is often successful in the management of RN. The objective of this study is to assess whether VEGF receptor (VEGFR) inhibitors, a group of oral tyrosine kinase inhibitors (TKIs), can prevent or reverse RN. METHODS: We retrospectively studied a cohort of 102 patients with renal cell carcinoma and brain metastases seen at The Ohio State University James Cancer Center between January 1, 2011 and April 30, 2019. We identified those who developed RN and analyzed the temporal relationship between the use of VEGFR TKIs and the development of RN. RESULTS: The cumulative incidence of RN is 13.7% after radiation treatments that included LINAC-based stereotactic radiosurgery, fractionated stereotactic radiotherapy, or Gamma Knife radiosurgery. There was no statistically significant difference in the cumulative incidence of RN between patients taking TKIs and patients who were off TKIs (9.9% and 11.5% respectively, P = .741). The median time to development of RN was only numerically shorter in patients taking TKIs (151 vs 315 days, P = .315). One patient developed RN after stopping cabozantinib. Eight patients developed RN while on cabozantinib, pazopanib, or sunitinib. One patient was started on axitinib during active RN without significant improvement subsequently. CONCLUSIONS: VEGFR TKIs do not consistently prevent RN. The therapeutic effects of VEGFR TKIs against RN warrant further research.
BACKGROUND: Radiation necrosis (RN) is a potential complication after radiation therapy for brain tumors. It is hypothesized that VEGF plays an important role in the pathophysiology of RN. Bevacizumab, a monoclonal antibody against VEGF-A, is often successful in the management of RN. The objective of this study is to assess whether VEGF receptor (VEGFR) inhibitors, a group of oral tyrosine kinase inhibitors (TKIs), can prevent or reverse RN. METHODS: We retrospectively studied a cohort of 102 patients with renal cell carcinoma and brain metastases seen at The Ohio State University James Cancer Center between January 1, 2011 and April 30, 2019. We identified those who developed RN and analyzed the temporal relationship between the use of VEGFR TKIs and the development of RN. RESULTS: The cumulative incidence of RN is 13.7% after radiation treatments that included LINAC-based stereotactic radiosurgery, fractionated stereotactic radiotherapy, or Gamma Knife radiosurgery. There was no statistically significant difference in the cumulative incidence of RN between patients taking TKIs and patients who were off TKIs (9.9% and 11.5% respectively, P = .741). The median time to development of RN was only numerically shorter in patients taking TKIs (151 vs 315 days, P = .315). One patient developed RN after stopping cabozantinib. Eight patients developed RN while on cabozantinib, pazopanib, or sunitinib. One patient was started on axitinib during active RN without significant improvement subsequently. CONCLUSIONS: VEGFR TKIs do not consistently prevent RN. The therapeutic effects of VEGFR TKIs against RN warrant further research.
Authors: Birk Poller; Dilek Iusuf; Rolf W Sparidans; Els Wagenaar; Jos H Beijnen; Alfred H Schinkel Journal: Drug Metab Dispos Date: 2011-01-31 Impact factor: 3.922
Authors: Simon Kirste; Markus Treier; Sabine Jolie Wehrle; Gerhild Becker; Mona Abdel-Tawab; Kathleen Gerbeth; Martin Johannes Hug; Beate Lubrich; Anca-Ligia Grosu; Felix Momm Journal: Cancer Date: 2011-02-01 Impact factor: 6.860
Authors: Nancy U Lin; Eudocia Q Lee; Hidefumi Aoyama; Igor J Barani; Daniel P Barboriak; Brigitta G Baumert; Martin Bendszus; Paul D Brown; D Ross Camidge; Susan M Chang; Janet Dancey; Elisabeth G E de Vries; Laurie E Gaspar; Gordon J Harris; F Stephen Hodi; Steven N Kalkanis; Mark E Linskey; David R Macdonald; Kim Margolin; Minesh P Mehta; David Schiff; Riccardo Soffietti; John H Suh; Martin J van den Bent; Michael A Vogelbaum; Patrick Y Wen Journal: Lancet Oncol Date: 2015-05-27 Impact factor: 41.316
Authors: Arkadiusz Z Dudek; Ahmad Raza; Ming Chi; Meghali Singhal; Rajneet Oberoi; Rajendar K Mittapalli; Sagar Agarwal; William F Elmquist Journal: Clin Genitourin Cancer Date: 2012-12-21 Impact factor: 2.872
Authors: Victor A Levin; Luc Bidaut; Ping Hou; Ashok J Kumar; Jeffrey S Wefel; B Nebiyou Bekele; Jai Grewal; Sujit Prabhu; Monica Loghin; Mark R Gilbert; Edward F Jackson Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-01 Impact factor: 7.038
Authors: Neda H Sadraei; Saurabh Dahiya; Samuel T Chao; Erin S Murphy; Kwabena Osei-Boateng; Hao Xie; John H Suh; David M Peereboom; Glen H J Stevens; Manmeet S Ahluwalia Journal: Am J Clin Oncol Date: 2015-06 Impact factor: 2.339
Authors: Michael Staehler; Nicolas Haseke; Philipp Nuhn; Cordula Tüllmann; Alexander Karl; Michael Siebels; Christian G Stief; Berndt Wowra; Alexander Muacevic Journal: BJU Int Date: 2010-12-13 Impact factor: 5.588
Authors: P J Chuba; P Aronin; K Bhambhani; M Eichenhorn; L Zamarano; P Cianci; M Muhlbauer; A T Porter; J Fontanesi Journal: Cancer Date: 1997-11-15 Impact factor: 6.860